Business
Rockwell Medical Announces Proposed Public Offering of Common Stock
WIXOM, Mich., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"WIXOM, Mich., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced an underwritten public offering of its common stock. In addition, Rockwell Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.\n Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Rockwell Medical anticipates using the net proceeds from the offering for the commercialization of Dialysate Triferic and I.V. Triferic, research and development and general corporate purposes. The securities described above are being offered by Rockwell Medical pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Rockwell Medical Rockwell Medical is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company’s initial focus is the treatment of anemia in end-stage renal disease (ESRD). Rockwell Medical's exclusive renal drug therapy, Triferic (ferric pyrophosphate citrate), is the only FDA-approved therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. The Company has developed multiple formulations of Triferic (1) FDA-approved Dialysate Triferic, an...